By Landon Gray
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA approve an investigational microbiota-based live biotherapeutic, RBX2660 (Ferring) to reduce recurrent Clostridioides difficile infection (CDI) after antibiotic treatment.
The committee reviewed data from Ferring’s biologics license application for RBX2660, which included six studies with 1,061 participants, of whom 978 were treated with the biotherapeutic. The study, a phase 3